The LIVE procedure, which is used to reshape and reduce the size of left ventricle (LV), was conducted at the Vilnius University Hospital in Vilnius, Lithuania, on a 61-year-old man who is suffering from advanced heart failure.
BioVentrix’s new Revivent-TC system uses a myocardial anchor similar to the company’s CE Marked Revivent myocardial anchoring system.
Recently, the company announced the publication of clinical results in the European Journal of Cardio-Thoracic Surgery demonstrating the durability of the Revivent system and these results are anticipated to continue with the new transcatheter delivery approach of the Revivent-TC system.
Surgical ventricular restoration, invasive procedure, is performed for reshaping the left ventricle prior to the Revivent and Revivent-TC systems use and this invasive nature of surgical ventricular restoration limits the use of this procedure due to the fragile nature of many heart failure patients.
The LIVE procedure requires no cardiopulmonary bypass or making incisions into the heart and now the Revivent-TC system also removes the need to open the patient’s chest.
BioVentrix president and CEO Kenneth Miller noted the company is very pleased with the outcome of this first-in-man LIVE procedure with the Revivent-TC system by the heart failure team in Lithuania.
"It is gratifying to accomplish this important step in our mission to develop and deliver heart failure therapy that treats the fundamental cause in the least invasive way possible, so that even very ill patients can benefit," Miller added.
